BIONET Corp. (TPEX:1784)

Market Cap	3.49B
Revenue (ttm)	1.22B
Net Income (ttm)	83.70M
Shares Out	50.83M
EPS (ttm)	1.65
PE Ratio	41.64
Forward PE	n/a
Dividend	1.41 (2.11%)
Ex-Dividend Date	Sep 19, 2024

Volume	132,091
Average Volume	328,938
Open	69.70
Previous Close	68.70
Day's Range	68.60 - 70.30
52-Week Range	55.98 - 162.01
Beta	0.59
RSI	38.74
Earnings Date	Mar 28, 2025

About BIONET

BIONET Corp. provides cell therapy services in Taiwan and internationally. The company offers stem cell banking services, including stem cell storage, mesenchymal stem cell storage, dental stem cell storage, adipose stem cell, and peripheral blood stem cells and immune cells; and genetic testing services. It also provides stem anti-aging and ANIKINE series products; and Exosome, a novel cell-free therapy. In addition, the company offers regenerative medicine, analytical testing, clinical and preclinical research, and commercialized cell-derived...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1989
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 1784

Financial Performance

In 2024, BIONET's revenue was 1.22 billion, an increase of 8.40% compared to the previous year's 1.13 billion. Earnings were 83.70 million, an increase of 6.76%.